Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jason Bailey

Physician Assistant, Medical Roanoke, VA Physician Assistant

NPI 1760567481 CMS profile 11053393

2110 Carolina Ave Sw Fl 3, Roanoke, VA 24014

Open in the dashboard

General payments

$10,366

476 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Bailey of Roanoke, VA is reported in the CMS Open Payments database as having received $10,366 across 476 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,963 149
2024 General $3,214 124
2023 General $1,877 92
2022 General $1,888 89
2021 General $424 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Bailey
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jason Bailey were reported at $2,963. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jason Bailey Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $424 $156 $41–$563 $132
2022 $1,888 $185 $55–$649 $149
2023 $1,877 $199 $58–$717 $160
2024 $3,214 $206 $62–$740 $164
2025 $2,963 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,407 107 payments
  2. Janssen Biotech, Inc. $1,055 62 payments
  3. Genzyme Corporation $629 26 payments
  4. Incyte Corporation $609 28 payments
  5. Hill Dermaceuticals, Inc. $580 4 payments
  6. Pfizer Inc. $580 41 payments
  7. UCB, Inc. $569 22 payments
  8. E.R. Squibb & Sons, L.L.C. $544 25 payments
  9. Regeneron Healthcare Solutions, Inc. $451 18 payments
  10. Lilly USA, LLC $446 24 payments
  11. Other $2,494 119 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,669 464 payments
  2. Education $697 12 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,071 39 payments
  2. RINVOQ $1,025 47 payments
  3. TREMFYA $1,015 59 payments
  4. SKYRIZI Immunology $972 40 payments
  5. OPZELURA $609 28 payments
  6. Tolak $580 4 payments
  7. SOTYKTU $544 25 payments
  8. CIBINQO $541 39 payments
  9. Bimzelx $500 18 payments
  10. SKYRIZI Immunology $454 20 payments
  11. Other $4,043 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,587

Median for Physician Assistant: 241

Drug cost

$696,040

Median for Physician Assistant: $4,110

Branded share of claims

8.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 30 $378,597
Cosentyx Sensoready (2 Pens) Secukinumab Brand 24 $198,520
Dupixent Syringe Dupilumab Brand 21 $78,297
Clobetasol Propionate Generic 287 $16,016
Clindamycin Phosphate Generic 95 $3,863
Metronidazole Generic 67 $3,314
Tretinoin Generic 30 $2,963
Ketoconazole Generic 171 $2,502
Doxycycline Hyclate Generic 122 $2,424
Triamcinolone Acetonide Generic 167 $1,903

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$157,574

Of which drugs: $936

Medicare patients

1,309

Average age 75

Services billed

5,200

657 women, 652 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 19%
Chronic kidney disease 19%
Depression 17%
Atrial fibrillation 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Tolak
  • Hill Dermaceuticals, Inc. $516
$516 — —
SKYRIZI
  • AbbVie, Inc. $434
$434 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $340
$340 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $118
  • GENZYME CORPORATION $105
  • SANOFI-AVENTIS U.S. LLC $80
$303 21 —
TREMFYA
  • Janssen Biotech, Inc. $273
$273 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

476 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record